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Abstract 
Most previous attempts to estimate the marginal productivity of English health care expenditure 
have employed instruments that rely on statistical tests alone for their justification. A new approach 
ƚŽŝŶƐƚƌƵŵĞŶƚĂƚŝŽŶŚĂƐƉƌŽƉŽƐĞĚƚŚĞƵƐĞŽĨ ‘ĨƵŶĚŝŶŐƌƵůĞ ?ǀĂƌŝĂďůĞƐĂƐŝŶƐƚƌƵŵĞŶƚƐ ?ǁŚŝĐŚĐĂŶďĞ
justified on theoretical grounds. We exploit the availability of a funding formula for local authority 
(LA) public health expenditure in England to investigate the relationship between such expenditure 
and mortality. Although there have been many studies of the impact of specific health promotion 
activities on outcomes, we are not aware of any successful attempts to relate English public health 
expenditure to mortality. Moreover, by converting healthcare (treatment) expenditure to a local 
authority geography, we are also able to estimate an outcome specification that includes both 
treatment (healthcare) and prevention (public health) expenditure. This enables us to identify the 
relative contribution of both types of expenditure to reductions in mortality. Previously published 
work has linked effects on disease specific mortality to changes in quality-adjusted life years. We use 
these estimates to report the cost per quality-adjusted life year (QALY) for both treatment and 
public health (prevention) expenditure.  
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1. Introduction 
Recent studies of the marginal productivity of National Health Service (NHS) expenditure in England 
suggest a cost per quality-adjusted life year (QALY) of between £5,000 and £15,000 (Claxton et al, 
2015; Lomas et al, 2018). These estimates imply that this expenditure provides good value for 
money when compared with the cost effectiveness threshold used by the National Institute for 
Health and Care Excellence (NICE) for the adoption of new health care technologies (between 
£20,000 and £30,000 per QALY). These estimates also suggest that marginal increases in health 
expenditure, whether funded through additional taxation, borrowing or reallocation from other 
spending departments, appear good value when compared to estimates of the equivalent 
consumption value of health (recent reviews suggest that £30,000 per QALY might represent a 
reasonable lower bound for this (Vallejo-Torres et al (2016); Ryen and Svensson (2015))). 
 
That NHS healthcare expenditure offers good value for money might be one reason why the current 
ŐŽǀĞƌŶŵĞŶƚ ?Ɛausterity programme affects almost all government spending, yet the NHS continues 
to be protected from direct spending cuts. Although the NHS has fared relatively well, the public 
health grant to local authorities is not part of the ring-fenced NHS. Instead, this element of public 
health expenditure is currently in the fourth year of a five-year funding squeeze that will see real 
spending per person fall by nearly one-fifth between 2015/16 and 2019/20 (Finch, 2018 and DH, 
2019). 
 
One justification for the simultaneous protection of the NHS budget and the reduction in the public 
health grant might be that expenditure on prevention offers relatively few health benefits. However, 
the available evidence appears to contradict this. For example, Public Health England (PHE) 
ŵĂŝŶƚĂŝŶƐĂ ‘ŚĞĂůƚŚĞĐŽŶŽŵŝĐĞǀŝĚĞŶĐĞƌĞƐŽƵƌĐĞ ? ?,Z ?ƚŽŽů  ?ĂǀĂŝůĂďůĞĂƚ
https://www.gov.uk/government/publications/health-economics-evidence-resource). This resource 
takes the form of a spreadsheet that reviews over 250 studies that examine the cost-effectiveness 
and return on investment associated with the activities that are ring-fenced within the English public 
health grant. The studies included in this resource suggest that public health activities provide 
generous returns. 
 
For those interested in the cost per QALY, Owen et al (2018) report the cost per QALY associated 
with public health interventions assessed by NICE over two five-year periods (between 2005 and 
2010, and between 2011 and 2016). Owen et al report that 85% of the public health interventions 
assessed by NICE during the first period were cost-effective at a threshold of £20,000 per QALY, and 
that the median cost per QALY was £1,053. During the second period, 63% of assessed interventions 
were cost-effective and the median cost per QALY was £7,843. Owen et al argue that the decline in 
the proportion of cost-effective interventions reflects the types of interventions and topic areas 
assessed in the two periods, rather than any underlying decline in the cost-effectiveness of public 
health interventions generally (Owen et al, 2018, p559). 
 
For those interested in the return on investment in public health interventions, Masters et al (2017) 
undertook a systematic review of 2,957 potentially relevant titles and ultimately included 52 studies 
published over four decades in their report. The local public health programmes included studies of 
fall prevention, smoking cessation and water fluoridation. The median return on investment (ROI) 
for all 29 local public health interventions was 4.1 to 1, and the median cost-benefit ratio (CBR) was 
10.3. The national public health programmes included studies of HIV/AIDS prevention, measles 
vaccination, and road safety campaigns, and generated even better returns (the median ROI for all 
28 nationwide public health interventions was 27.2 to 1, and the median CBR was 17.5). 
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This distinction  ? between local and national public health programmes  ? is also reflected in the 
funding for public health expenditure in England. The public health grant delegates responsibility for 
local public health expenditure decisions to local commissioners (to local authorities). National 
public health programmes (eg for national immunisation and national screening programmes) are 
the responsibility of the NHS Commissioning Board. In 2013/14 the public health grant for local 
commissioning was £2.5bn, and the national public health functions exercised by the NHS 
Commissioning Board attracted a budget of £2.2bn (DH, 2012a). Here, our focus is on the impact of 
the public health grant because we do not have data for expenditure on national programmes by 
local area. 
 
The studies reported by PHE, and discussed by Masters et al, typically focus on individual public 
health interventions, whereas the h< ?Ɛausterity programme imposes a reduction in the total public 
health grant to local authorities. Any evaluation of this policy will need to quantify the benefits 
forgone through the reduction in the totality of expenditure, rather than the losses associated with 
reductions in individual parts of the public health programme. The only readily available health 
outcome measure that is potentially applicable to the public health grant is mortality and hence, in 
this paper, we seek to estimate the relationship between this outcome indicator and variations in 
the public health grant across local authorities. 
 
We readily acknowledge that, for some public health expenditure, the health benefits might arise 
many years after the expenditure has occurred. This is particularly likely to be the case where 
expenditure is directed at encouraging healthy lifestyles, where some benefits may occur two or 
three decades after the actual expenditure. However, this study is constrained by the available 
public health expenditure data and comparable mortality data. Implicitly, we are assuming that the 
data represent a quasi long-run equilibrium situation, that relative expenditure levels and health 
outcomes within each LA have been reasonably stable over a period of time, and that any lag of 
effect of current expenditure on future mortality is offset by the impact of previous expenditure on 
current mortality. These seem to be not unreasonable assumptions in the English context, and 
Brown reports that, in his Californian study, just over half of the cumulative lives saved as a result of 
a single year of public health spending occurred in the two years immediately following that 
expenditure (Brown, 2016, p.1480). Although there are several American studies of the relationship 
between mortality and public health expenditure at the US county level (see, for example, Brown 
(2014) and Leider et al (2018)), we are not aware of any British studies on this topic. Moreover, given 
the very different healthcare system in the UK, the American results might not be relevant for 
Britain. 
 
Studies of the relationship between mortality and any type of health expenditure often struggle with 
the endogeneity of expenditure. Two recent developments enable us to overcome this issue. First, a 
recent paper ƉƌŽƉŽƐĞĚƚŚĞƵƐĞŽĨ ‘ĨƵŶĚŝŶŐƌƵůĞ ?ǀĂƌŝĂďůĞƐĂƐŝŶƐƚƌƵŵĞŶƚƐĨŽƌĞǆƉĞŶĚŝƚƵƌĞǁŚĞŶ
estimating the relationship between healthcare expenditure and mortality (Andrews et al, 2017). 
However, this approach relies on the existence ŽĨĂ ‘ĨƵŶĚŝŶŐĨŽƌŵƵůĂ ?that allocates the national 
budget across local commissioners and, before 2013/14, there was no specific funding formula for 
the public health grant. Second, the Health and Social Care Act 2012 transferred responsibility for 
local public health expenditure from local healthcare commissioners (Primary Care Trusts) to local 
government (to single and  ‘upper tier ? local authorities). This transfer took effect from April 2013 
and, at the same time, a  ‘funding formula ? was introduced. This formula split the national public 
health grant between the 152 LAs and provides analysts with potential instruments for this public 
health expenditure (DH, 2012b). 
 
In this paper, we exploit the availability of a funding formula for the public health grant to 
investigate the relationship between such expenditure and mortality  The most recent mortality data 
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available at a local level is for 2013/2014/2015 combined, and hence we relate expenditure in 
2013/14 to a measure of mortality for these three years. Although there have been many studies of 
the impact of specific health promotion activities on outcomes, we are not aware of any successful 
attempts to relate English public health expenditure to mortality. Moreover, by converting 
healthcare (treatment) expenditure as reported by Clinical Commissioning Groups (CCGs) to a local 
authority geography, we are also able to estimate an outcome specification that includes both 
treatment (healthcare) and prevention (public health) expenditure. This enables us to identify the 
relative contribution of both types of expenditure to reductions in mortality. Previously published 
work has linked effects on disease specific mortality to changes in quality-adjusted life years (eg 
Claxton et al, 2015). We use these estimates to report the cost per quality-adjusted life year (QALY) 
for both treatment and public health (prevention) expenditure. 
 
The structure of this paper is as follows. Section 2 provides information about the definition of public 
health expenditure used here, together with details of the institutional arrangements for healthcare 
and public health provision in England during the study period. Section 2 also provides details of the 
outcome equation to be estimated, together with our estimation strategy. The dataset is discussed 
in section 3 and results are presented in section 4. The results are discussed in section 5 with some 
concluding remarks in section 6.  
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2. The institutional context, public health and healthcare expenditure, and 
estimation strategy 
Institutional context 
The English National Health Service (NHS) is a largely centrally planned and publicly funded health 
care system. Its income comes almost entirely from national taxation. Access to the Service is usually 
via general practitioners who act as gatekeepers to secondary care and pharmaceuticals. With some 
minor exceptions, the service is free at the point of consumption for patients. The Service is 
organised geographically, with responsibility for the local management of the NHS delegated to local 
health authorities. For our study year (2013/14), each authority (CCG) was assigned a fixed annual 
budget by the national ministry (the Department of Health), within which they were supposed to 
meet expenditure on most types of health care except primary care, specialised commissioning and 
public health. Primary care, specialised commissioning and national public health programmes were 
administered centrally. Responsibility for local public health was delegated to local government with 
ĞĂĐŚ ‘ƵŶŝƚĂƌǇ ?ŽƌƵƉƉĞƌƚŝĞƌĂƵƚŚŽƌŝƚǇƌĞĐĞŝǀŝŶŐĂĨŝǆĞĚĂŶŶual budget, ring-fenced for public health 
activities. 
 
Public health expenditure 
ĐĐŽƌĚŝŶŐƚŽƚŚĞh< ?ƐEĂƚŝŽnal Audit Office (NAO), public health is about helping people to stay 
healthy, and protecting them from threats to their health. In England, public health activities include 
ƉƌŽƚĞĐƚŝŶŐƚŚĞƉƵďůŝĐ ?ƐŚĞĂůƚŚĨƌŽŵŚĂǌĂƌĚƐĂŶĚŝŶĨĞĐƚŝŽƵƐĚŝƐĞĂƐĞƐ ?ŝŵƉƌŽǀŝŶŐƚŚĞ ƉƵďůŝĐ ?ƐŚĞĂůƚh via 
the encouragement of healthier lifestyles, and reducing health inequalities (HC 888, 2014, p11).1 
 
In 2013/14, the public health grant from the Department of Health, enabled local authorities to 
spend over £2,500m on public health services including £630m on sexual health services (eg for STI 
testing and treatment, and for contraception), £800m on substance (drugs and alcohol) misuse 
services, £150m on stop smoking and tobacco control services, and £240m on health programmes 
for children aged 5-19 (see MCHLG, 2015). In addition, £2,203m was made available for national 
public health programmes, including those for immunisation (eg for Hepatitis B, BCG, and MMR) and 
for screening (eg for exposure to HIV and for cervical cancer) (see DH (2012a) for further details). 
 
Healthcare expenditure 
As noted above, the Health and Social Care Act 2012 replaced Primary care trusts (PCTs) with CCGs 
as commissioners of local healthcare and stripped them of their responsibility for primary care, 
specialised commissioning, and public health  Nevertheless, this still left CCGs with a budget of 
£65bn for 2013/14 and we use their reported expenditure from the programme budgeting dataset 
as a measure of local healthcare expenditure (NHS England, 2015). 
 
In this ƐƚƵĚǇǁĞƐŽŵĞƚŝŵĞƐƌĞĨĞƌƚŽƉƵďůŝĐŚĞĂůƚŚĞǆƉĞŶĚŝƚƵƌĞĂƐ ‘ƉƌĞǀĞŶƚĂƚŝǀĞ ?ĂŶĚŚĞĂůƚŚĐĂƌĞ
expenditure aƐ ‘ƚƌĞĂƚŵĞŶƚ ? ?ĨŽƌŝůů-health). This is more out of a desire to avoid repetition rather than 
any belief that all expenditure funded by the public health grant is preventative and/or that all 
healthcare expenditure is solely for treatment. For example, some expenditure from the public 
health grant could be considered as treatment (eg expenditure on substance misuse treatment 
                                                             
1 On this definition, public health activities will neither be confined to the Department of Health nor rely on government 
expenditure  Expenditure by other government departments, such as those responsible for housing and transport, will also 
impact on public health. Similarly, changes to national regulations that involve little or no government spending (such as 
the introduction of plain packaging for cigarettes and the Soft Drinks Industry levy) will also impact on public health. Both 
of these aspects of policy are beyond the scope of this study. 
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services) and some expenditure by CCGs will be preventative (eg on medication for blood pressure 
and blood cholesterol). 
 
As one very rough guide to the volume of preventative expenditure by CCGs, programme budgeting 
ĚĂƚĂĨŽƌ ? ? ? ? ? ? ?ƌĞƉŽƌƚƐĂƚŽƚĂůƐƉĞŶĚŽĨ ? ? ? ?ŵŝŶƚŚĞ ‘,ĞĂůƚŚǇ/ŶĚŝǀŝĚƵĂůƐ ?ƉƌŽŐƌĂŵŵĞŽĨǁŚŝĐŚ
 ? ? ? ?ŵŝƐĨŽƌ ‘ƉƌĞƐĐƌŝďŝŶŐŝŶƉƌŝŵĂƌǇĐĂƌĞ ?ĂŶĚ ? ? ? ?ŵŝƐĨŽƌ ‘ĐŽŵŵƵŶŝƚǇĂŶĚŝŶƚĞŐƌĂƚĞĚĐĂƌĞ ? (NHS 
England, 2015). In principle, we could add this expenditure (£411m) to that from the public health 
grant (£2,500m) to obtain an overall measure of public health spend. However, as the precise set of 
activities covered by this CCG  ‘,ĞĂůƚŚǇ/ŶĚŝǀŝĚƵĂůƐ ?expenditure is unclear and there are always issues 
about how consistently different CCGs allocate activity to different programme budget categories, 
we prefer to focus on the public health grant as our measure of public health expenditure. We 
ŝŶĐůƵĚĞƚŚĞ ‘,ĞĂůƚŚǇ/ŶĚŝǀŝĚƵĂůƐ ?ƐƉĞŶĚĂƐƉĂƌƚŽĨƚŚĞƚŽƚĂůŵĞĂƐƵƌĞŽĨŚĞĂůƚŚĐĂƌĞ ?ƚƌĞĂƚŵĞŶƚ ?
expenditure. Our estimates of the impact of the public health grant and CCG expenditure will largely 
reflect  ‘ƉƌĞǀĞŶƚŝŽŶ ? and  ‘ƚƌĞĂƚŵĞŶƚ ?ĞĨĨĞĐƚƐrespectively, but we acknowledge that there will be 
relatively small elements of treatment expenditure in the prevention measure, and relatively small 
elements of prevention expenditure in the treatment measure. 
 
Estimation strategy 
Studies estimating the relationship between any form of health expenditure and mortality typically 
estimate an outcome equation of the form: 
 
ln (mortality rate) = ln (health expenditure per person) + controls for need + e              (1) 
 
where expenditure is likely to be endogenous, the controls reflect the need for health expenditure, 
and e reflects everything not included elsewhere in the specification (Andrews et al, 2017; Claxton et 
al, 2018). We want to estimate this specification, first with public health as the sole expenditure 
variable, and then with both public health and healthcare expenditure as two separate variables. 
 
One issue with the estimation of (1) is that the endogeneity of expenditure will necessitate the use 
of instruments for this variable. The resource allocation formula for the public health grant to local 
authorities has three components  ? for mandatory services, for non-mandatory services, and for 
substance misuse services  ? and each component has its own formula. Although the precise formula 
differs for each component, overall, the public health budget per person can be expressed as: 
 
local budget per person= (national budget per person) x (local age index) x 
 
  (local additional needs index) x (local input price index) x (local DFT Index)              (2) 
 
where: (a) the age index reflects the demographic profile of the local population; (b) the additional 
needs index reflects local deprivation and other factors likely to influence the need for public health 
expenditure; (c) the input price index (MFF) reflects prices in the local health economy; and (d) the 
distance from target (DFT) index reflects how far each LA ?ƐĂĐƚƵĂůďƵĚŐĞƚĂůůŽĐĂƚŝŽn is from its target 
allocation  The latter reflects the fact that, periodically, the national ministry revises the funding 
formula and this, together with routine data updates, generates a new target budget allocation for 
each LA. For some LAs, the new funding rule might generate a large change in its target allocation 
and, to avoid sudden large reductions in actual allocations (budgets), such changes are phased into 
actual budgets over a number of years in accordance with the Department of Health ?Ɛ ‘ƉĂĐĞŽĨ
change ? policy (see DH (2012b) for details). 
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Two of the four adjustment factors in equation (2)  ? the MFF and the DFT  ? are relevant for all three 
components of the public health resource allocation formula for 2013/14 and provide instruments 
for expenditure if there is no direct connection between them and our measure of mortality. The 
local input price index (MFF), which will reflect characteristics of the local (health) economy, could 
be correlated with unmeasured determinants of mortality. However, we have over a dozen potential 
socio-economic covariates (including the Index of Multiple Deprivation) in the baseline mortality 
equation and, hence, it is difficult to imagine what effect the input price index would detect that our 
covariates do not.2 The DFT variable will largely reflect: (i) the level of PCT expenditure in 2010/11 
associated with those public health activities that were transferred to local authorities in 2013/14;3 
(ii) the public health grant funding formula for 2013/14; and (iii) ƚŚĞ ‘ƉĂĐĞŽĨĐŚĂŶŐĞ ?ƉŽůŝĐǇĨŽƌthe 
2013/14 allocations. The latter two factors will be policy choices but it is not obvious that the 
resulting DFT will be endogenous with respect to mortality. Moreover, any correlation between our 
two instruments and the error term in equation (1) is likely to be detected by the Hansen-Sargan 
test. Hence we use the public health grant MFF and DFT as instruments for public health expenditure 
when estimating equation (1). 
 
Theory provides little guidance as to the identity of the appropriate controls in equation (1) so, 
following previous studies, we identify a dozen socio-economic variables -- such as the proportion of 
the working-age population employed in managerial and professional occupations, and the 
proportion of owner-occupied households  ? as potential controls for the need for public health 
expenditure (Claxton et al, 2018)  We start by estimating (1) with all socio-economic variables 
included as controls. The least significant regressor is removed from the specification and the 
equation is re-estimated. This process  ? of dropping the least significant regressor and re-estimating 
-- continues until there are only significant controls remaining (the expenditure term is forced to be 
ever-present). This specification becomes our preferred result if it also passes the appropriate 
statistical tests (eg the instruments are valid and the instruments are strong) but, if this is not the 
case, the specification is adjusted (eg an invalid instrument is removed) and the equation re-
estimated. When the specification requires no further adjustment it becomes our preferred 
specification. 
 
Initially, equation (1) is estimated using the above strategy with public health as the sole health 
expenditure variable. We then re-estimate (1)  ? again using the above strategy  ? but this time 
including healthcare expenditure as an additional endogenous regressor. This variable is 
instrumented in a similar way to public health. However, the identification of the relevant funding 
rule variables is slightly complicated because of the changes imposed by the Health and Social Care 
Act 2012. Usually, funding formulae are updated every year but the impending abolition of PCTs 
meant that the weighted capitation formula was frozen for 2012-13, with all PCTs receiving the same 
(3%) growth rate over their 2011/12 allocations. As CCG responsibilities in 2013/14 differed from 
those for PCTs (eg they lost responsibility for public health, specialised services, and primary care), 
there was a baseline exercise in 2012 which stripped out actual expenditure on these components 
and, for 2013-14, each CCG was given an uplift of 2.3% on these 2012 baselines (DH, 2018). 
                                                             
2 Of course, if a locality gets a larger budget to compensate for the higher cost of supplying healthcare, as happens with the 
local price index, and this adjustment exactly compensates for additional costs, then there is no reason why this additional 
spending should improve health because it does not correspond to an increase in real spending. In reality, of course, the 
ĐŽƐƚĂĚũƵƐƚŵĞŶƚǁŝůůŶŽƚďĞƉĞƌĨĞĐƚ ?^ŽŵĞůŽĐĂůĂƵƚŚŽƌŝƚŝĞƐǁŝůůďĞŽǀĞƌĐŽŵƉĞŶƐĂƚĞĚĂŶĚŚĞŶĐĞƌĞĐĞŝǀĞ ‘ƚŽŽŵƵĐŚ ?
ĨƵŶĚŝŶŐ ?ŽƚŚĞƌƐǁŝůůďĞƵŶĚĞƌĐŽŵƉĞŶƐĂƚĞĚĂŶĚƌĞĐĞŝǀĞ ‘ƚŽŽƐŵĂůů ?ĂďƵĚŐĞƚ. This imperfect adjustment for local conditions 
provides the link between this instrument, expenditure and mortality. The same argument applies to the use of the age 
index as an instrument for healthcare expenditure discussed later. 
 
3 A baseline survey was undertaken in 2011 to establish how much each PCT spent in 2010/11 on those public health 
activities that were to be transferred to local authorities in 2013/14. This was to ensure that each LA would be able to at 
least match the expenditure level recorded by PCTs. 
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The implication of these developments for this study is that the best funding rule variables we can 
identify for CCG healthcare expenditure in 2013/14 are drawn from the 2011/12 allocations for PCTs, 
appropriately mapped to the new (CCG) geography. These allocations reflect three separate funding 
formulae (one for Hospital and Community Services (HCHS), one for prescribing, and one for primary 
care), and we select three funding rule variables employed in these formulae which we believe are 
uncorrelated with mortality. In particular, our funding rule variables for healthcare expenditure are: 
(i) the DFT for the total allocation to PCTs for 2011/12; (ii) the MFF for the HCHS component of the 
total allocation; and (iii) the age index from the prescribing component of the total allocation. The 
DFT variable is available from ƚŚĞĞƉĂƌƚŵĞŶƚŽĨ,ĞĂůƚŚ ?ƐǁĞďƐŝƚĞĂƚ
https://www.networks.nhs.uk/nhs-networks/health-investment-network/news/2012-13-
programme-budgeting-data-is-now-available (accessed 09 January 2019), and the MFF and age 
indices are available from the exposition books for the 2011/12 allocations at 
https://www.gov.uk/government/publications/exposition-book-2011-2012 (accessed 09 January 
2019). 
 
Andrews et al provide no explicit arguments in support of their instruments for healthcare 
expenditure but this omission is easily remedied. First, our measure of mortality and the age index 
instrument are both standardised for age, and so the age index is unlikely to be correlated with the 
error from equation (1). Second, and as already noted when discussing the instruments for public 
health expenditure, the local input price index will reflect characteristics of the local (health) 
economy that can be correlated with unmeasured determinants of mortality. However, we have 
over a dozen potential socio-economic covariates in the baseline mortality equation and hence it is 
difficult to imagine what effect the MFF would detect that our covariates do not. Third, the DFT 
ǀĂƌŝĂďůĞĨŽƌŚĞĂůƚŚĐĂƌĞĂůůŽĐĂƚŝŽŶƐǁŝůůƌĞĨůĞĐƚƚŚĞǀĂƌŝŽƵƐĨƵŶĚŝŶŐĨŽƌŵƵůĂĞĂŶĚ ‘ƉĂĐĞŽĨĐŚĂŶŐĞ ?
policies implemented under several governments of various political persuasions over the past thirty 
years. It is certainly the case that the 'pace of change' and the consequent DFT are policy choices but 
it is not obvious that the latter will be endogenous with respect to mortality. And, as noted above for 
the instruments for public health expenditure, any correlation between our instruments and the 
error term in equation (1) is likely to be detected by the Hansen-Sargan test. 
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3. Data 
Unitary and upper tier local authorities (n=152) are the unit of analysis in this study but one of them 
(the Isles of Scilly) is so small that the mortality data for this authority is rarely disclosed by the ONS 
so this leaves 151 authorities for analysis. In addition, the healthcare expenditure data for one CCG 
(Wiltshire) for 2013/14 has not been reported (reliability issues) so that, when both expenditure 
variables are included in the estimating equation, there are 150 observations for analysis. 
 
With the exception of the CCG healthcare expenditure and the instruments for this variable, all of 
the dataset is readily available at the local authority (LA) level. The healthcare expenditure and 
instrument data have been converted to a LA basis using a mapper which uses population levels in 
mid-2012 to allocate (parts of) CCGs to LAs. As LAs vary greatly in size, we weight all observations in 
our analysis by their population size. In addition, we use the logarithms of all variables in the 
empirical analysis so that regression coefficients can be interpreted as elasticities. 
 
Table 1 reports descriptive statistics for the variables employed in this study. Average expenditure 
per person from the public health grant in 2013/14 was £53 and this varied between £18 and £186 
per person.4 Average per capita expenditure on healthcare was £1,152. The mortality measure 
employed in this study is the (age) standardised under 75 years of life lost rate (SYLLR). The latest 
release of mortality data (for 2013/14/15 combined) is available via the NHS Digital Indicator portal 
at https://indicators.hscic.gov.uk/webview/. This mortality rate varies considerably across the 
country, ranging between 267 (City of London) and 776 (Blackpool) years of life lost per 10,000 
population. 
 
The DFT instrument for public health expenditure averages just over 1.00 but its range suggests that 
at least one LA budget is 46% under its target allocation and another LA budget (the City of London) 
is 562% above its target allocation. The MFF instrument for public health expenditure reveals that 
some LAs face unit costs between 8% lower and 21% higher than the average. The instruments for 
healthcare expenditure also reveal considerable geographic variation with, for example, some LAs 
being 7% below and others being 23% above their target allocations.5 
 
The dozen potential socio-economic controls for the need for health are also listed in Table 1. These 
census-based variables are constructed using the 2011 census. They show that, for example, on 
average, 13% of all residents are born outside the European Union, 31% of the working-age 
population are employed in managerial and professional occupations, and 62% of households are 
owner occupied. Again, these averages mask considerable variation across local authorities; the 
proportion of residents born outside the EU varies from less than 2% to more than 50%, and the 
extent of owner occupation ranges between 26% and 81% of all households. 
 
 
                                                             
4 dŚĞĞǆƉĞŶĚŝƚƵƌĞĨŝŐƵƌĞĨŽƌ ? ? ? ? ? ? ?ŝƐďĞĨŽƌĞĐŚŝůĚƌĞŶ ?Ɛ ?ĂŐĞĚ ?-5 years) public health services were transferred from 
central administration (NHS England) to local administration (LAs). This took place in October 2015 and, in the first full year 
(2016/17) under LA responsibility, these services accounted for £930m of expenditure. 
 
5 It should be emphasised that all instruments are designed to reflect the position in 2013/14 and not the current 
(2018/19) situation. 
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Table 1 Descriptive statistics for study variables 
Variable description Observations Mean Std. Dev. Minimum Maximum 
Health expenditure variables 
     
Public health grant: expenditure per person, £, 2013/14 152 52.6 25.2 18.5 186.2 
Healthcare spend per person, £, 2013/14 151 1152.1 75.8 1019.9 1479.1       
Mortality variable 
     
Standardised years of life lost rate, 2013/14/15 151 443.3 85.0 267.5 775.9       
Instruments for expenditure 
     
Distance from target (public health), 2013/14 152 1.0667 0.5362 0.5392 6.6247 
Market Forces Factor (public health), 2013/14 152 1.0122 0.0790 0.9151 1.2076 
Distance from target (healthcare: total), 2013/14 152 1.0055 0.0515 0.9282 1.2250 
Age index (healthcare: prescribing), 2013/14 152 0.9776 0.1283 0.6422 1.3007 
Market Forces Factor (healthcare: HCHS), 2013/14 152 1.0063 0.0643 0.9319 1.1416       
Socio-economic controls 
     
Proportion of all residents born outside the European Union 152 0.1281 0.1147 0.0144 0.5060 
Proportion of population in white ethnic group 152 0.8364 0.1626 0.2897 0.9882 
Proportion of population providing unpaid care 152 0.1008 0.0138 0.0651 0.1289 
Proportion of population aged 16-74 with no qualifications 152 0.2469 0.0606 0.0720 0.3874 
Proportion of households without a car 152 0.2862 0.1248 0.0899 0.6940 
Proportion of households that are owner occupied 152 0.6190 0.1152 0.2611 0.8086 
Proportion of households that are one pensioner households, 2011 152 0.1206 0.0208 0.0596 0.1667 
Proportion of households that are lone parent households with dependent children 152 0.0745 0.0185 0.0208 0.1436 
Proportion of population aged 16-74 that are permanently sick 152 0.0424 0.0149 0.0086 0.0879 
Proportion of those aged 16-74 that are long-term unemployed 152 0.0183 0.0058 0.0043 0.0367 
Proportion of those aged 16-74 in employment that are working agriculture 152 0.0064 0.0099 0.0003 0.0572 
Proportion of those aged 16-74 in managerial and professional occupations 152 0.3114 0.0769 0.1835 0.6674 
Index of multiple deprivation (2010) 152 23.0753 8.6040 5.4466 43.4465 
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4. Results 
With the public health grant as the only expenditure variable 
Estimation of equation (1) with public health as the sole expenditure variable generates the result 
shown in column 1 of Table 2. The corresponding first-stage result can be found in column 1 of Table 
A1 in the appendix. Application of the backward selection process generates the more parsimonious 
specification shown in column 2 of Table 2. Public health expenditure has the anticipated negative 
association with mortality but this specification fails the reset test and the instrument set is invalid 
(the Hansen-Sargan test statistic p-value<0.100). The addition of IMD 2010 squared to the 
specification resolves the reset test but not the instrument validity issue (column 3). The result in 
column 4 omits that instrument (the MFF index) which is the most significant when added as a 
control to the second-stage equation. The significant positive coefficient (0.252) on the  ‘white 
ethnicity ? variable might reflect a lifestyle effect but, in the interests of clarity, we re-estimate 
without this variable and obtain the result shown in column 5. The coefficient ŽŶƚŚĞ ‘ƉĞƌŵĂnently 
ƐŝĐŬ ?ǀĂƌŝĂďůĞŝŶĐƌĞĂƐĞƐĐŽŶƐŝĚĞƌĂďůǇ(from 0.265 to 0.475) and the coefficient on the  ‘ǁŽƌŬŝŶŐŝŶ
ĂŐƌŝĐƵůƚƵƌĞ ?ǀĂƌŝĂďůĞŝƐŶŽůŽŶŐĞƌƐŝŐŶŝĨŝĐĂŶƚ ?ZĞ-estimation without the latter variable generates our 
preferred specification shown in column 6. In this, public health expenditure has a modest but 
statistically significant negative association with mortality, expenditure is endogenous, there is no 
evidence of weak instruments (the Kleibergen-Paap F statistic exceeds the rule-of-thumb threshold 
value (=10)), and the specification passes the reset test. 
 
With both the public health grant and healthcare as the expenditure variables: backward 
selection 
Estimation of equation (1) with both public health and healthcare expenditure as endogenous 
regressors generates the result shown in column 1 of Table 3. This specification includes five 
instruments (two for public health expenditure and three for healthcare expenditure). The 
corresponding first-stage results can be found in column 1 (for public health) and in column 2 (for 
healthcare) in Table A2 in the appendix. 
 
Some authors have expressed concern about the inclusion of weak instruments (for example, Small, 
2007) and hence we re-estimate the  ‘ĨƵůů ? specification without the two insignificant MFF 
instruments (see column 2 of Table 3). Application of the backward selection process generates the 
more parsimonious result shown in column 3 but the instrument set is invalid at the 1% level. On 
checking to see if any of the deleted variables or their squared values are significant when added as 
a control to the second-stage, we found that tŚĞ ‘ƉĞƌŵĂŶĞŶƚůǇƐŝĐŬ ?ǀĂƌŝĂďůĞŝƐďŽƚŚƐŝŐŶŝĨŝĐĂŶƚĂŶĚ
resolves the weak instrument issue for healthcare expenditure. Again, in the interests of clarity, we 
tried re-estimating the specification in column 4 without the  ‘ǁŚŝƚĞĞƚŚŶŝĐŝƚǇ ?ǀĂƌŝĂďůĞ. This 
generates the plausible result shown in column 5 where both expenditure variables have the 
anticipated negative association with mortality, they are endogenous, the instrument set is valid, 
and the instrument sets for both endogenous variables are individually strong (the Sanderson-
Windmeijer F-statistics are around ten or better). 
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Table 2 Derivation of preferred specification for public health expenditure, 2013/14 
  (1) 
All causes 
2013/14 PH spend 
SYLLR 2013/14/15 
outcome model 
instrument PH 
spend weighted 
IV second stage 
full specification 
(2) 
All causes 
2013/14 PH spend 
SYLLR 2013/14/15 
outcome model 
instrument PH 
spend weighted 
IV second stage 
new derivation 
(3) 
All causes 
2013/14 PH spend 
SYLLR 2013/14/15 
outcome model 
instrument PH 
spend weighted 
IV second stage 
new derivation 
revised1 
(4) 
All causes 
2013/14 PH spend 
SYLLR 2013/14/15 
outcome model 
instrument PH 
spend weighted 
IV second stage 
new derivation 
revised2 
(5) 
All causes 
2013/14 PH spend 
SYLLR 2013/14/15 
outcome model 
instrument PH 
spend weighted 
IV second stage 
new derivation 
revised2 
(6) 
All causes 
2013/14 PH spend 
SYLLR 2013/14/15 
outcome model 
instrument PH 
spend weighted 
IV second stage 
new derivation 
revised2 
 
 
 
 
 
 
 
 
 
VARIABLES 
    
SA_1 SA_2 
              
Public health spend per person 
-0.084** -0.122*** -0.108** -0.119*** -0.116** -0.115** 
[0.041] [0.046] [0.043] [0.043] [0.047] [0.048] 
IMD 2010 
0.203*** 0.152** -0.271* -0.374** -0.509*** -0.505*** 
[0.075] [0.063] [0.141] [0.146] [0.163] [0.157] 
Proportion of all residents born outside the EU 
-0.016 
     
[0.018] 
     
Proportion of population in white ethnic group 
0.246*** 0.261*** 0.249*** 0.252*** 
  
[0.060] [0.039] [0.038] [0.038] 
  
Proportion of population providing unpaid care 
-0.439*** -0.346*** -0.271*** -0.235*** -0.235*** -0.231** 
[0.167] [0.088] [0.083] [0.084] [0.090] [0.091] 
Proportion of population aged 16-74 with no 
qualifications 
-0.034 
     
[0.112] 
     
Proportion of households without a car 
-0.062 
     
[0.072] 
     
Proportion of households that are owner occupied 
0.129* 
     
[0.071] 
     
Proportion of households that are one pensioner 
households 
-0.082 
     
[0.084] 
     
Lone parent households with dependent children 
0.056 
     
[0.060] 
     
Proportion of population aged 16-74 that are 
permanently sick 
0.315*** 0.319*** 0.284*** 0.265*** 0.475*** 0.475*** 
[0.070] [0.077] [0.071] [0.072] [0.067] [0.068] 
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Proportion of those aged 16-74 that are long-term 
unemployed 
0.039 
     
[0.057] 
     
Proportion of those aged 16-74 working agriculture 
-0.015 -0.025*** -0.020*** -0.016** 0.001 
 
[0.010] [0.007] [0.007] [0.007] [0.007] 
 
Proportion of those aged 16-74 in professional 
occupations 
-0.201*** -0.268*** -0.243*** -0.230*** -0.204*** -0.205*** 
[0.077] [0.044] [0.046] [0.047] [0.050] [0.049] 
IMD 2010 Squared 
  
0.078*** 0.100*** 0.093*** 0.092***   
[0.026] [0.027] [0.029] [0.028] 
Constant 
5.532*** 5.895*** 6.514*** 6.710*** 7.941*** 7.936*** 
[0.649] [0.349] [0.393] [0.402] [0.397] [0.402]        
Observations 151 151 151 151 151 151 
Endogeneity test statistic 11.369 10.449 8.572 15.109 13.881 10.579 
Endogeneity p-value 0.001 0.001 0.003 0.000 0.000 0.001 
Hansen-Sargan test statistic 14.750 10.957 14.408 
   
Hansen-Sargan p-value 0.000 0.001 0.000 
   
Kleibergen-Paap LM test statistic 26.821 34.909 35.502 34.884 34.868 32.762 
Kleibergen-Paap p-value 0.000 0.000 0.000 0.000 0.000 0.000 
Kleibergen-Paap F statistic 69.320 88.578 99.555 192.280 185.421 120.521 
Pesaran-Taylor reset statistic 10.116 6.248 0.599 0.469 2.422 2.456 
Pesaran-Taylor p-value 0.001 0.012 0.439 0.493 0.120 0.117 
Robust standard errors in brackets 
      
*** p<0.01, ** p<0.05, * p<0.1 
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Table 3 Derivation of preferred specification for public health expenditure with healthcare expenditure, backward selection, 2013/14 
  (1) (2) (3) (4) (5)  
All causes All causes All causes All causes All causes  
2013/14 PH & PB 
spend 
2013/14 PH & PB 
spend 
2013/14 PH & PB 
spend 
2013/14 PH & PB 
spend 
2013/14 PH & PB 
spend  
SYLLR 2013/14/15 SYLLR 2013/14/15 SYLLR 2013/14/15 SYLLR 2013/14/15 SYLLR 2013/14/15  
outcome model outcome model outcome model outcome model outcome model  
instrument PH&PB 
spend 
instrument PH&PB 
spend 
instrument 
PH&PB spend 
instrument 
PH&PB spend 
instrument 
PH&PB spend  
weighted weighted weighted weighted weighted  
IV second stage IV second stage IV second stage IV second stage IV second stage  
backward selection backward selection backward 
selection 
backward 
selection 
backward 
selection  
full specification full specification derived 
specification 
derived 
specification 
derived 
specification 
VARIABLES five instruments three instruments three instruments revised revised 
            
Public health spend per person, 2013/14 
-0.024 -0.052 0.010 -0.037 -0.081** 
[0.037] [0.038] [0.033] [0.034] [0.034] 
Healthcare spend per person, 2013/14 
-0.551 -0.076 -0.869*** -0.662*** -0.672*** 
[0.413] [0.355] [0.233] [0.204] [0.233] 
IMD 2010 
0.253*** 0.231*** 0.271*** 0.281*** 0.221*** 
[0.062] [0.078] [0.067] [0.063] [0.063] 
Proportion of all residents born outside the EU 
-0.043* -0.023 -0.054*** -0.042** -0.084*** 
[0.024] [0.023] [0.020] [0.019] [0.019] 
Proportion of population in white ethnic group 
0.226*** 0.237*** 0.192*** 0.185*** 
 
[0.051] [0.058] [0.034] [0.036] 
 
Proportion of population providing unpaid care 
-0.399*** -0.466*** -0.376*** -0.372*** -0.479*** 
[0.144] [0.165] [0.099] [0.096] [0.096] 
Proportion of population aged 16-74 with no qualifications 
-0.111 -0.089 
   
[0.105] [0.124] 
   
Proportion of households without a car 
-0.033 -0.091 
   
[0.087] [0.083] 
   
Proportion of households that are owner occupied 
0.090 0.103 
   
[0.075] [0.074] 
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Proportion of households that are one pensioner households 
-0.023 -0.035 
   
[0.079] [0.087] 
   
Lone parent households with dependent children 
-0.048 0.023 
   
[0.082] [0.090] 
   
Proportion of population aged 16-74 that are permanently sick 
0.237*** 0.281*** 0.176** 0.910*** 1.187*** 
[0.068] [0.070] [0.077] [0.343] [0.331] 
Proportion of those aged 16-74 that are long-term unemployed 
0.085 0.069 
   
[0.060] [0.067] 
   
Proportion of those aged 16-74 working agriculture 
-0.007 -0.012 
   
[0.013] [0.010] 
   
Proportion of those aged 16-74 in professional occupations 
-0.259*** -0.243*** -0.244*** -0.223*** -0.194*** 
[0.072] [0.083] [0.039] [0.040] [0.045] 
Proportion of population aged 16-74 that are permanently sick, 
squared 
   
0.111** 0.138***    
[0.053] [0.052] 
Constant 
8.714*** 5.636** 10.645*** 10.605*** 11.286*** 
[2.852] [2.502] [1.379] [1.132] [1.409]       
Observations 150 150 150 150 150 
Endogeneity test statistic 5.928 9.295 6.089 9.906 17.683 
Endogeneity p-value 0.052 0.010 0.048 0.007 0.000 
Hansen-Sargan test statistic 20.849 9.099 6.810 6.458 1.667 
Hansen-Sargan p-value 0.000 0.003 0.009 0.011 0.197 
Kleibergen-Paap LM test statistic 9.027 6.363 16.219 15.540 16.034 
Kleibergen-Paap p-value 0.060 0.042 0.000 0.000 0.000 
Kleibergen-Paap F statistic 2.323 2.663 9.390 8.971 8.979 
Pesaran-Taylor reset statistic 1.405 6.440 0.528 0.330 0.175 
Pesaran-Taylor p-value 0.236 0.011 0.467 0.565 0.676 
Sanderdson-Windmejer Public health spend F-statistic 70.796 36.048 51.105 78.626 70.796 
Sanderdson-Windmejer Public health spend p-value 0.000 0.000 0.000 0.000 0.000 
Sanderdson-Windmejer Healthcare spend F-statistic 13.469 3.008 4.288 13.427 13.469 
Sanderdson-Windmejer Healthcare spend p-value 0.000 0.021 0.016 0.000 0.000 
Robust standard errors in brackets 
     
*** p<0.01, ** p<0.05, * p<0.1 
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With both the public health grant and healthcare as the expenditure variables: forward 
selection 
The use of backward selection to identify relevant covariates, when theory provides little guidance, 
does not always meet with universal approval, and hence we also report results using forward 
selection (see Table 4). Column 1 shows the result with the inclusion of the most significant single 
ĐŽŶƚƌŽů ? ‘ƉĞƌŵĂŶĞŶƚůǇƐŝĐŬ ? ?ǁŝƚŚƚŚĞƐĂŵĞĨŝǀĞŝŶƐƚƌƵŵĞŶƚƐĨƌŽŵƚŚĞ ‘ĨƵůů ? specification in Table 3. 
The Hansen-Sargan test statistic suggests that the instrument set is not valid and, in response to this, 
we re-estimate without the two insignificant MFF instruments. This re-estimation (see column 2, 
Table 4) largely resolves the instrument validity issue. Further re-estimation, with the inclusion of 
additional significant controls, generates the results shown in columns 3, 4 and 5. No further 
additional significant controls could be found and, as the result in column 5 is both in line with both 
our theoretical priors and passes the appropriate statistical tests, this is our preferred specification 
using forward selection.
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Table 4 Derivation of preferred specification for public health expenditure with healthcare expenditure, forward selection, 2013/14 
  (1) (2) (3) (4) (5)  
All causes All causes All causes All causes All causes  
2013/14 PH & PB 
spend 
2013/14 PH & PB 
spend 
2013/14 PH & PB 
spend 
2013/14 PH & PB 
spend 
2013/14 PH & PB 
spend  
SYLLR 2013/14/15 SYLLR 2013/14/15 SYLLR 2013/14/15 SYLLR 2013/14/15 SYLLR 2013/14/15  
outcome model outcome model outcome model outcome model outcome model  
instrument PH&PB 
spend 
instrument PH&PB 
spend 
instrument PH&PB 
spend 
instrument PH&PB 
spend 
instrument PH&PB 
spend  
weighted weighted weighted weighted weighted  
IV second stage IV second stage IV second stage IV second stage IV second stage  
forward selection forward selection forward selection forward selection forward selection  
round 1 round 1 round 2 round 3 round 4 
VARIABLES five instruments three instruments three instruments three instruments three instruments 
            
Public health spend per person, 2013/14 
-0.006 -0.004 -0.128*** -0.107*** -0.144*** 
[0.025] [0.028] [0.040] [0.041] [0.040] 
Healthcare spend per person, 2013/14 
-1.012*** -1.394*** -0.949*** -1.190*** -0.837*** 
[0.244] [0.266] [0.238] [0.263] [0.269] 
Proportion of population aged 16-74 that are 
permanently sick 
0.554*** 0.603*** 0.697*** 0.707*** 0.601*** 
[0.031] [0.035] [0.046] [0.046] [0.051] 
Proportion of population providing unpaid care 
  
-0.289*** -0.571*** -0.547***   
[0.081] [0.134] [0.122] 
Proportion of all residents born outside the EU 
   
-0.059*** -0.070***    
[0.021] [0.019] 
Proportion of those aged 16-74 that are long-term 
unemployed 
    
0.156***     
[0.040] 
Constant 
15.008*** 17.848*** 14.831*** 15.692*** 13.666*** 
[1.756] [1.913] [1.719] [1.742] [1.762]       
Observations 150 150 150 150 150 
Endogeneity test statistic 6.137 17.111 21.226 20.194 22.853 
Endogeneity p-value 0.046 0.000 0.000 0.000 0.000 
Hansen-Sargan test statistic 23.780 2.997 0.032 1.702 1.465 
Hansen-Sargan p-value 0.000 0.083 0.857 0.192 0.226 
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Kleibergen-Paap LM test statistic 24.002 19.635 19.756 17.814 18.331 
Kleibergen-Paap p-value 0.000 0.000 0.000 0.000 0.000 
Kleibergen-Paap F statistic 7.220 10.806 12.647 11.051 11.627 
Pesaran-Taylor reset statistic 0.073 0.054 0.069 0.005 0.466 
Pesaran-Taylor p-value 0.788 0.816 0.793 0.946 0.495 
Sanderdson-Windmejer Public health spend F-
statistic 
100.608 183.202 76.326 66.169 57.002 
Sanderdson-Windmejer Public health spend p-value 0.000 0.000 0.000 0.000 0.000 
Sanderdson-Windmejer Healthcare spend F-statistic 9.052 16.288 19.070 16.633 17.375 
Sanderdson-Windmejer Healthcare spend p-value 0.000 0.000 0.000 0.000 0.000 
Robust standard errors in brackets 
     
*** p<0.01, ** p<0.05, * p<0.1 
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5. Discussion 
The estimation of a mortality equation that includes both public health and healthcare expenditure 
has generated an outcome elasticity for public health expenditure of -0.081 using backward 
selection and an elasticity of -0.144 using forward selection. The mid-point of these two elasticities is 
almost identical to the elasticity estimated without the inclusion of health care expenditure (=-
0.115). Although statistically significant, these elasticities appear relatively modest when compared 
with the elasticity associated with healthcare expenditure (which, in this paper, is several times 
larger than the public health elasticity). However, this comparison is misleading because it fails to 
allow for the relative size of the two budgets. 
 
The coefficient on public health expenditure from column 6 of Table 1 implies that a 1% increase in 
such expenditure (=£25.107m) in 2013/14 is associated with a 0.115% decline in the number of life 
years lost. However, a change in expenditure, which has an observed effect on mortality, is also 
likely to have effects on a more complete measure of health which captures the impact on survival 
and quality of life. Therefore, to convert the estimated all-cause elasticity into a likely QALY effect of 
public health expenditure we would ideally require evidence of the effects of public health 
expenditure on both all-cause mortality and on QALYs. 
 
Direct estimates of the QALY effects of public health expenditure are not available. However, 
previous work has estimated the mortality and QALY effects of changes in NHS healthcare 
expenditure and these can be used to give some indication of the possible QALY effects of public 
health expenditure. For example, NHS healthcare expenditure can be divided between 23 care 
programmes (PBCs) and, for those (10) programmes with a mortality indicator, an outcome equation 
similar to equation (2) can be estimated (Claxton et al, 2015). Drawing on a number of data sources, 
Claxton et al estimate the QALY burden of disease for each 3-digit ICD10 code within each PBC.6 
They calculate the QALY burden of disease for each PBC by summing (over all relevant ICD10 codes) 
the product of the per patient QALY burden and the size of the population with the disease 
(prevalent and incident) in one year. For each PBC with a mortality based outcome elasticity, the 
estimated change in QALYs associated with, say, a 1% change in total expenditure is the product of 
the outcome elasticity for total expenditure and the QALY burden for the PBC (i.e., effects on the 
ŵŽƌƚĂůŝƚǇďƵƌĚĞŶŽĨĚŝƐĞĂƐĞĂƌĞƵƐĞĚĂƐĂ ‘ƐƵƌƌŽŐĂƚĞ ?ĨŽƌĞĨĨĞĐƚƐŽŶƚŚĞďƌŽĂĚĞƌY>zďƵƌĚĞŶ ? ?7 For 
those PBCs without an outcome indicator, Claxton et al (2015) calculate the average proportionate 
effect of a change in expenditure on the mortality burden of disease in those PBCs where mortality-
based outcome elasticities can be estimated, and this average is used as a proxy for the outcome 
elasticity for those PBCs without a directly estimated outcome elasticity (i.e., the proportionate 
effects on burden of disease are extrapolated from where they can be observed to where they 
cannot). 
 
Using the same approach to estimating the QALY burden of disease, and the same surrogacy and 
extrapolation assumptions, Lomas et al (2018) update the Claxton et al (2015) results. Lomas et al 
                                                             
6 Data from WHO global burden of disease study was used to estimate the duration and incidence of disease (by age and 
gender), ONS data provided mortality conditional life expectancies by age and gender, quality of life norms by age and 
gender were based on data from the Health Survey for England and the impact of disease on these quality of life norms 
were provided by Health Outcomes Data Repository (HODaR) supplemented with information from the Medical 
Expenditure Panel Survey (MEPS). 
 
7 Claxton et al (2015) use own programme expenditure rather than all programme expenditure in their outcome equations, 
and they also estimate an expenditure equation for each PBC. The latter reveals what proportion of any change in total 
expenditure is spent in that PBC. Therefore, the PBC outcome elasticity for total expenditure, which is applied to the QALY 
burden of diseases within the PBC, is the product of the outcome and expenditure elasticities estimated in Claxton et al 
(2015). 
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report that, in 2012/13, a 1% change in total healthcare expenditure generates 65,773 QALYs across 
all disease areas. Although Lomas et al (2018) do not directly estimate an all-cause mortality 
elasticity, the programme-specific elasticities that they do estimate imply an all-cause mortality of -
1.028. This suggests that a 1% reduction in all-cause mortality is associated with a gain of 63,981 
QALYs (65,773/1.028). Therefore, a 1% increase in public health expenditure (£25.107m), which 
reduces all-cause mortality by 0.115% maybe associated with a gain of 7,358 QALYs (0.115 x 63,981). 
This 7,358 QALY gain, together with the additional expenditure of £25.107m, implies a cost per QALY 
for public health of £3,412. 
 
Similar calculations can be made for the two other public health elasticities (-0.081 and -0.144) 
reported in Table 5, and the implied cost per QALY estimates are £4,845 and £2,725 respectively. 
Moreover, we can use the same information from Lomas et al (2018) to convert the all-cause 
healthcare elasticities in Table 5 into cost per QALY estimates. The backward selection elasticity (=-
0.672) implies a cost per QALY of £14,912, while the forward selection elasticity (=-0.837) implies a 
cost per QALY of £11,973. 
 
Table 5 Mortality elasticities and cost per quality adjusted life year estimates for public health and 
healthcare expenditure, 2013/14 
 
 
If we compare the average of the backward and forward selection estimates, then public health 
expenditure appears to be about three to four times more productive than healthcare expenditure 
(that is, the prevention cost per QALY is about £3,800 whereas the treatment cost per QALY is 
£13,500). This finding  ? that public health offers a much better return than healthcare at the margin 
 ? is also reported by other (American) studies (eg by Brown, 2014 and by Leider et al, 2018). We can 
also compare our (marginal) cost per QALY estimates for the public health grant with the median 
cost per QALY associated with public health interventions assessed by NICE between 2005 and 2010, 
and between 2011 and 2016 (Owen et al, 2018). Owen et al report a median cost per QALY of £1,053 
for the first period and £7,843 for the second period. Our estimate of the marginal cost per QALY 
(about £3,800) is about halfway between the two Owen et al figures. 
 
We can also compare our cost per QALY estimates for the public health grant with the return on 
investment associated with the public health interventions studied by Masters et al (2017). Across 
both local and national interventions, Masters et al report a median return on investment (ROI) of 
14.3 to 1. Putting aside average versus marginal differences, we can convert the cost per QALY 
associated with the public health grant (of about £3,800) into a societal ROI of about 15 to 1, if we 
assume that the value of a QALY is about £60,000.8 Thus our cost per QALY estimates are very much 
                                                             
8dŚĞh< ?ƐĞƉĂƌƚŵĞŶƚŽĨ,ĞĂůƚŚĂŶĚ,DdƌĞĂƐƵƌǇŚĂǀĞĂĚŽƉƚĞĚĂǀĂůƵĞŽĨ ? ? ? ? ? ? ?Ɖer QALY based primarily on the value 
of a statistical life from revealed preference studies. 
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in line with the findings from other studies (such as Owen et al and Masters et al) that have used 
very different data sets and different approaches to estimation. 
 
Our findings suggest that, at the margin, public health expenditure is very productive of health and 
more productive than NHS expenditure. This suggests that the reallocation of resources from NHS to 
public health is likely to improve health outcomes overall, and that the squeeze on the public health 
grant, while protecting NHS expenditure, over recent years is likely to have reduced health 
outcomes. It also means that the health opportunity costs of the public health grant are high, so new 
investments in public health interventions and programmes need to offer less than £3,800 per QALY 
to be accommodated within current levels of funding. However, this analysis also shows that NHS 
expenditure is also productive of health and the health opportunity costs faced are higher than 
those implied by the norms used to judge whether new technologies are cost-effective. The cost per 
QALY for NHS expenditure reported here is similar to previous estimates where public health 
expenditure was excluded (Claxton et al 2018, Lomas et al 2018). This suggests that including other 
categories of health expenditure in the outcome equation is unlikely to materially change estimates 
of the marginal productivity of NHS expenditure. 
 
However, linking the estimated effects on mortality to QALYs requires a number of assumptions 
(Claxton et al 2015 and Lomas et al 2018). The plausibility of these assumptions has been examined 
through structured elicitation from clinical experts (Soares et al 2018), and suggests that these are 
likely to be conservative with respect to the QALY effects of changes in expenditure, i.e., the cost per 
QALY is likely to be lower. Applying the QALY effects associated with changes in mortality from 
Lomas et al 2018 assumes the mortality effects of public health expenditure is distributed across 
disease areas in a similar way to NHS expenditure. However, in so far as public health expenditure 
tends to have greater effects on mortality in areas of high QALY burden of disease, such as 
respiratory and cardiovascular disease then the QALY effects will tend to be higher. Therefore, 
although there remains uncertainty about the cost per QALY associated with NHS and public health 
expenditure, the broad implications appear robust. 
 
Although our results are plausible, this study is not without its limitations. First, our focus is on the 
impact of the public health grant (£2.5bn in 2013/14). This delegates responsibility for local public 
health expenditure decisions to local commissioners (to local authorities). National public health 
programmes (eg for national immunisation and national screening programmes) are the 
responsibility of the NHS Commissioning Board and the impact of these is not considered here 
because we do not have data for expenditure on national programmes by local area. In addition, 
there will be some treatment expenditure within the public health grant, and there will be some 
prevention spend within the measure of CCG healthcare expenditure but we believe that this cross-
contamination will be relatively small. 
 
Second, and perhaps most importantly, equation (1) is static in the sense that it assumes that all 
health benefits occur contemporaneously with expenditure. However, our empirical implementation 
of (1) does slightly better than this, because our outcome measure reflects not only mortality in the 
same year as expenditure but also in the two subsequent years. Moreover, Brown reports that, in his 
Californian study, just over half of the cumulative lives saved as a result of a single year of public 
health spending occurred in the two years immediately following that expenditure (Brown, 2016, 
p.1480). Nevertheless, we readily acknowledge that, for some public health expenditure, the health 
benefits might arise many years after the expenditure has occurred. This is particularly likely to be 
the case where expenditure is directed at encouraging healthy lifestyles, where some benefits may 
occur two or three decades after the actual expenditure. 
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However, this study is constrained by the available public health expenditure data which are almost 
exclusively cross-sectional (a funding formula for public health was first introduced in 2013/14). 
Implicitly, we are assuming that the data represent a quasi long-run equilibrium situation, that 
relative expenditure levels and health outcomes within each LA have been reasonably stable over a 
period of time, and that any lag of effect of current expenditure on future mortality is offset by the 
impact of previous expenditure on current mortality. These seem to be not unreasonable 
assumptions in the English context but they are just assumptions, and they might be less appropriate 
for other geographies where, for example, relative outcomes have changed through time. 
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6. Concluding remarks 
Previous studies of the return to public health expenditure have tended to focus on particular 
interventions (eg the MMR vaccine). Most studies of total public health expenditure have used 
American data where the health care system is very different to that in the UK. In this paper we have 
exploited the introduction of a  ‘funding formula ? for the English public health grant in 2013/14 to 
estimate the responsiveness of mortality to variations in this component of public health 
expenditure and, by drawing on previous studies, we have been able to convert these mortality 
effects into broader QALY effects. 
 
Our cost per QALY estimate (about £3,800) for the totality of the public health grant is broadly 
consistent with the average effect identified by two recent reviews of specific public health 
interventions. This similarity gives us confidence in our results. Although our results suggest that the 
outcome elasticity for the public health grant is relatively modest compared with that for healthcare 
expenditure, this is a misleading comparison because it ignores the relative size of the two budgets. 
Cost per QALY calculations reveal that public health expenditure, at about £3,800 per QALY, appears 
to be about three to four times more productive at the margin than healthcare expenditure (which 
costs about £13,500 per QALY). dŚƵƐĞŶũĂŵŝŶ&ƌĂŶŬůŝŶ ?ƐĂǆŝŽŵ ?ƚŚĂƚ ‘ĂŶŽƵŶĐĞŽĨƉƌĞǀĞŶƚŝŽŶŝƐ
ǁŽƌƚŚĂƉŽƵŶĚŽĨĐƵƌĞ ? ?is correct in this context in the sense that prevention is more productive 
than cure but, with 16 ounces to the pound, the adage rather exaggerates the size of this advantage. 
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Appendix 
First-stage regression results for the second-stage specifications reported in the main body of the text. 
Table A1 First-stage regression results for derivation of preferred specification for public health expenditure, 2013/14 
  (1) (2) (3) (4) (5) (6)  
All causes All causes All causes All causes All causes All causes  
2013/14 PH spend 2013/14 PH spend 2013/14 PH spend 2013/14 PH spend 2013/14 PH spend 2013/14 PH spend  
SYLLR 2013/14/15 SYLLR 2013/14/15 SYLLR 2013/14/15 SYLLR 2013/14/15 SYLLR 2013/14/15 SYLLR 2013/14/15  
outcome model outcome model outcome model outcome model outcome model outcome model  
first-stage first-stage first-stage first-stage first-stage first-stage  
weighted weighted weighted weighted weighted weighted  
OLS OLS OLS OLS OLS OLS  
full specification new derivation new derivation new derivation new derivation new derivation    
revised1 revised2 revised2 revised2 
VARIABLES 
    
SA_1 SA_2 
              
DFT index_Public health_1314 
0.729*** 0.747*** 0.762*** 0.759*** 0.759*** 0.739*** 
[0.062] [0.056] [0.054] [0.055] [0.056] [0.067] 
MFF Index_Public health_1314 
-0.655* -0.559 -0.565 
   
[0.350] [0.348] [0.352] 
   
IMD 2010 
0.122 0.139 -0.590 -0.548 -0.599* -0.931** 
[0.137] [0.113] [0.388] [0.357] [0.357] [0.388] 
Proportion of all residents born outside the EU 
0.031 
     
[0.050] 
     
Proportion of population in white ethnic group 
0.309* 0.020 0.028 0.095 
  
[0.178] [0.083] [0.080] [0.071] 
  
Proportion of population providing unpaid care 
-0.113 -1.099*** -1.008*** -0.903*** -0.904*** -1.150*** 
[0.393] [0.161] [0.167] [0.151] [0.155] [0.180] 
Proportion of population aged 16-74 with no 
qualifications 
-0.277 
     
[0.185] 
     
Proportion of households without a car 
0.141 
     
[0.136] 
     
Proportion of households that are owner occupied 
-0.179 
     
[0.157] 
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Proportion of households that are one pensioner 
households 
-0.439* 
     
[0.238] 
     
Lone parent households with dependent children 
-0.001 
     
[0.112] 
     
Proportion of population aged 16-74 that are 
permanently sick 
0.326** 0.532*** 0.489*** 0.471*** 0.550*** 0.573*** 
[0.133] [0.120] [0.124] [0.124] [0.103] [0.116] 
Proportion of those aged 16-74 that are long-term 
unemployed 
0.046 
     
[0.099] 
     
Proportion of those aged 16-74 working agriculture 
-0.070*** -0.080*** -0.074*** -0.066*** -0.060*** 
 
[0.021] [0.013] [0.013] [0.012] [0.011] 
 
Proportion of those aged 16-74 in professional 
occupations 
-0.339** -0.100 -0.052 -0.115 -0.105 -0.008 
[0.146] [0.095] [0.096] [0.098] [0.096] [0.100] 
IMD 2010 Squared 
  
0.133** 0.132** 0.129** 0.204***   
[0.064] [0.059] [0.060] [0.064] 
Constant 
2.542** 2.020*** 3.146*** 3.191*** 3.658*** 3.929*** 
[1.116] [0.578] [0.829] [0.804] [0.683] [0.753]        
Observations 151 151 151 151 151 151 
Robust standard errors in brackets 
      
*** p<0.01, ** p<0.05, * p<0.1 
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Table A2 First-stage regression results for derivation of preferred specification for public health expenditure with healthcare expenditure, backward selection, 2013/14 
  (1) (2) (3) (4) (5) (6) (7) (8) (9) (10)  
All causes All causes All causes All causes All causes All causes All causes All causes All causes All causes  
2013/14 PH 
spend 
2013/14 PB 
spend 
2013/14 PH 
spend 
2013/14 PB 
spend 
2013/14 PH 
spend 
2013/14 PB 
spend 
2013/14 PH 
spend 
2013/14 PB 
spend 
2013/14 PH 
spend 
2013/14 PB 
spend  
SYLLR 
2013/14/15 
SYLLR 
2013/14/15 
SYLLR 
2013/14/15 
SYLLR 
2013/14/15 
SYLLR 
2013/14/15 
SYLLR 
2013/14/15 
SYLLR 
2013/14/15 
SYLLR 
2013/14/15 
SYLLR 
2013/14/15 
SYLLR 
2013/14/15  
outcome 
model 
outcome 
model 
outcome 
model 
outcome 
model 
outcome 
model 
outcome 
model 
outcome 
model 
outcome 
model 
outcome 
model 
outcome 
model  
first-stage first-stage first-stage first-stage first-stage first-stage first-stage first-stage first-stage first-stage  
weighted weighted weighted weighted weighted weighted weighted weighted weighted weighted  
OLS OLS OLS OLS OLS OLS OLS OLS OLS OLS  
backward 
selection 
backward 
selection 
backward 
selection 
backward 
selection 
backward 
selection 
backward 
selection 
backward 
selection 
backward 
selection 
backward 
selection 
backward 
selection  
full 
specification 
full 
specification 
full 
specification 
full 
specification 
derived 
specification 
derived 
specification 
derived 
specification 
derived 
specification 
derived 
specification 
derived 
specification 
VARIABLES five 
instruments 
five 
instruments 
three 
instruments 
three 
instruments 
three 
instruments 
three 
instruments 
revised revised revised revised 
                      
DFT index_Public health_1314 
0.727*** -0.029 0.724*** -0.028 0.748*** 0.018 0.750*** 0.017 0.746*** 0.017 
[0.056] [0.021] [0.057] [0.022] [0.054] [0.027] [0.052] [0.028] [0.056] [0.028] 
Healthcare_DFT_index 
0.427 0.351** 0.360 0.410*** 0.715** 0.614*** 0.548* 0.671*** 0.403 0.669*** 
[0.437] [0.138] [0.407] [0.146] [0.312] [0.153] [0.330] [0.161] [0.343] [0.155] 
Prescribing_Age_index 
-1.067*** 0.016 -1.201*** 0.037 -1.490*** 0.208*** -1.380*** 0.169** -1.233*** 0.172** 
[0.271] [0.083] [0.263] [0.082] [0.240] [0.074] [0.269] [0.078] [0.242] [0.069] 
MFF Index_Public health_1314 
1.264 0.490 
        
[1.106] [0.378] 
        
HCHS_MFF_index 
-1.921 -0.240 
        
[1.232] [0.388] 
        
IMD 2010 
0.126 -0.018 0.179 -0.046 0.132 0.028 0.215* -0.000 0.162 -0.001 
[0.137] [0.054] [0.134] [0.055] [0.105] [0.057] [0.112] [0.059] [0.116] [0.056] 
Proportion of all residents born 
outside the EU 
0.014 -0.034** 0.003 -0.037*** 0.022 -0.042*** 0.019 -0.041*** -0.021 -0.041*** 
[0.049] [0.013] [0.049] [0.013] [0.033] [0.013] [0.034] [0.013] [0.029] [0.013] 
Proportion of population in white 
ethnic group 
0.284 0.007 0.322* -0.025 0.239** -0.007 0.209* 0.004 
  
[0.175] [0.041] [0.182] [0.042] [0.098] [0.041] [0.109] [0.042] 
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Proportion of population 
providing unpaid care 
0.024 -0.029 0.128 -0.080 -0.123 -0.275*** -0.136 -0.270*** -0.303 -0.273*** 
[0.328] [0.105] [0.344] [0.109] [0.221] [0.088] [0.222] [0.087] [0.199] [0.078] 
Proportion of population aged 16-
74 with no qualifications 
-0.212 -0.055 -0.252 -0.048 
      
[0.154] [0.063] [0.157] [0.064] 
      
Proportion of households without 
a car 
0.095 0.124*** 0.082 0.112*** 
      
[0.137] [0.039] [0.140] [0.040] 
      
Proportion of households that are 
owner occupied 
-0.042 -0.000 -0.057 -0.036 
      
[0.127] [0.049] [0.123] [0.047] 
      
WƌŽƉŽƌƚŝŽŶŽĨŚ ?ŚŽůĚƐƚŚĂƚĂƌĞŽŶĞ
pensioner households 
-0.052 0.080 -0.042 0.073 
      
[0.283] [0.057] [0.268] [0.060] 
      
Lone parent households with 
dependent children 
-0.010 -0.162*** -0.061 -0.143*** 
      
[0.116] [0.037] [0.103] [0.037] 
      
Proportion of aged 16-74 that are 
permanently sick 
0.342*** 0.030 0.331** 0.034 0.487*** 0.030 1.285** -0.246 1.542*** -0.242 
[0.128] [0.055] [0.128] [0.057] [0.124] [0.066] [0.572] [0.217] [0.492] [0.207] 
Proportion of those 16-74 that are 
long-term unemployed 
0.055 0.089*** 0.056 0.093*** 
      
[0.084] [0.033] [0.086] [0.033] 
      
Proportion of those aged 16-74 
working agriculture 
-0.038* 0.019*** -0.034* 0.015** 
      
[0.019] [0.006] [0.019] [0.006] 
      
Proportion of those aged 16-74 in 
professional occupations 
-0.298** -0.097** -0.351** -0.069 -0.157* -0.063* -0.105 -0.081** -0.079 -0.080** 
[0.132] [0.047] [0.135] [0.047] [0.092] [0.037] [0.102] [0.038] [0.104] [0.037] 
Proportion of 16-74 that are 
permanently sick, squared 
      
0.132 -0.046 0.161** -0.045       
[0.089] [0.034] [0.080] [0.033] 
Constant 
3.987*** 7.244*** 3.774*** 7.249*** 4.584*** 6.254*** 5.539*** 5.923*** 5.737*** 5.927*** 
[1.015] [0.401] [1.017] [0.399] [0.680] [0.347] [0.886] [0.438] [0.854] [0.428]            
Observations 150 150 150 150 150 150 150 150 150 150 
Robust standard errors in brackets 
          
*** p<0.01, ** p<0.05, * p<0.1 
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Table A3 First-stage regression results for derivation of preferred specification for public health expenditure with healthcare expenditure, forward selection, 2013/14 
 
(1) (2) (3) (4) (5) (6) (7) (8) (9) (10)  
All causes All causes All causes All causes All causes All causes All causes All causes All causes All causes  
2013/14 PH 
spend 
2013/14 PB 
spend 
2013/14 PH 
spend 
2013/14 PB 
spend 
2013/14 PH 
spend 
2013/14 PB 
spend 
2013/14 PH 
spend 
2013/14 PB 
spend 
2013/14 PH 
spend 
2013/14 PB 
spend  
SYLLR 
2013/14/15 
SYLLR 
2013/14/15 
SYLLR 
2013/14/15 
SYLLR 
2013/14/15 
SYLLR 
2013/14/15 
SYLLR 
2013/14/15 
SYLLR 
2013/14/15 
SYLLR 
2013/14/15 
SYLLR 
2013/14/15 
SYLLR 
2013/14/15  
outcome 
model 
outcome 
model 
outcome 
model 
outcome 
model 
outcome 
model 
outcome 
model 
outcome 
model 
outcome 
model 
outcome 
model 
outcome 
model  
first-stage first-stage first-stage first-stage first-stage first-stage first-stage first-stage first-stage first-stage  
weighted weighted weighted weighted weighted weighted weighted weighted weighted weighted  
OLS OLS OLS OLS OLS OLS OLS OLS OLS OLS  
forward 
selection 
forward 
selection 
forward 
selection 
forward 
selection 
forward 
selection 
forward 
selection 
forward 
selection 
forward 
selection 
forward 
selection 
forward 
selection  
round 1 round 1 round 1 round 1 round 2 round 2 round 3 round 3 round 4 round 4 
VARIABLES five 
instruments 
five 
instruments 
three 
instruments 
three 
instruments 
three 
instruments 
three 
instruments 
three 
instruments 
three 
instruments 
three 
instruments 
three 
instruments 
                      
DFT index_Public health_1314 
0.729*** 0.025 0.728*** 0.026 0.725*** 0.024 0.723*** 0.009 0.715*** 0.007 
[0.055] [0.026] [0.056] [0.026] [0.058] [0.025] [0.061] [0.025] [0.059] [0.026] 
MFF Index_Public health_1314 
0.832 0.550 
        
[1.006] [0.416] 
        
Healthcare_DFT_index 
0.633** 0.579*** 0.504* 0.552*** 0.373 0.457*** 0.383 0.526*** 0.447 0.542*** 
[0.291] [0.127] [0.272] [0.116] [0.279] [0.119] [0.277] [0.114] [0.285] [0.115] 
Prescribing_Age_index 
-1.591*** 0.143** -1.530*** 0.147*** -1.326*** 0.296*** -1.338*** 0.206*** -1.263*** 0.225*** 
[0.146] [0.059] [0.095] [0.039] [0.199] [0.068] [0.228] [0.067] [0.235] [0.070] 
HCHS_MFF_index 
-1.335 -0.729 
        
[1.119] [0.450] 
        
Proportion of 16-74 that are 
permanently sick 
0.639*** 0.065*** 0.673*** 0.073*** 0.711*** 0.101*** 0.710*** 0.094*** 0.654*** 0.080*** 
[0.049] [0.018] [0.030] [0.012] [0.042] [0.016] [0.044] [0.015] [0.054] [0.022] 
Proportion of population 
providing unpaid care 
    
-0.260 -0.189*** -0.268 -0.250*** -0.304 -0.259*** 
     
[0.193] [0.067] [0.193] [0.069] [0.193] [0.071] 
Proportion of all residents born 
outside the EU 
      
-0.004 -0.030*** -0.016 -0.033***       
[0.026] [0.010] [0.027] [0.011] 
30  CHE Research Paper 166 
Proportion of 16-74 that are 
long-term unemployed 
        
0.091 0.023         
[0.058] [0.028] 
Constant 
5.844*** 7.257*** 5.958*** 7.286*** 5.490*** 6.945*** 5.458*** 6.708*** 5.534*** 6.727*** 
[0.157] [0.057] [0.096] [0.040] [0.357] [0.125] [0.388] [0.146] [0.395] [0.144] 
Observations 
          
150 150 150 150 150 150 150 150 150 150 
Robust standard errors in brackets 
          
*** p<0.01, ** p<0.05, * p<0.1 
          
 
